Henry Kaminski is a Neurology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2150 Pennsylvania Ave., NW
Washington Dc, DC 20037
Telephone
202-741-2700Registry record last updated 24 Jun 2014.
Clinical trials
- Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
Sponsor: University of Alabama at Birmingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB SAProgram year20255 payments$21,634openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Merck Healthcare KGaAProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
54%Corticosteroid54%Prednisone100%Part D≥43 patientsNervous system
26.6%Cholinesterase Inhibitor26.6%Pyridostigmine Bromide100%Part D≥27 patientsCancer & immunology
13.5%Calcineurin inhibitor8.4%Tacrolimus100%Part D<11 patientsPurine Antimetabolite5.1%Azathioprine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Project 1 Clinical Procedures to Support Research in Myasthenia Gravis (CAPTURE_MG)
George Washington University
FY2026$444,160U54NS115054
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”